Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing
- PMID: 16232020
- DOI: 10.1592/phco.2005.25.11.1566
Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing
Abstract
Patients with various rheumatologic and inflammatory disease states commonly require drugs known to decrease the inflammatory or autoimmune response for adequate control of their condition. Such drugs include nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. These drugs affect inflammation and local immune responses, which are necessary for proper wound healing in the perioperative setting, thereby potentially resulting in undesirable postoperative complications. Such complications include wound dehiscence, infection, and impaired collagen synthesis. The end result is delayed healing of soft tissue and bone wounds. The current literature provides insight into the effect of some of these drugs on wound healing. For certain drugs, such as methotrexate, trials have been conducted in humans and direct us on what to do during the perioperative period. Whereas with other drugs, we must rely on either small-animal studies or extrapolation of data from human studies that did not specifically look at wound healing. Unfortunately, no clear consensus exists on the need and optimum time for withholding therapy before surgery. Likewise, clinicians are often uncertain of the appropriate time to resume therapy after the procedure. For those drugs with limited or no data in this setting, the use of pharmacokinetic properties and biologic effects of each drug should be considered individually. In some cases, discontinuation of therapy may be required up to 4 weeks before surgery because of the long half-lives of the drugs. In doing so, patients may experience an exacerbation or worsening of disease. Clinicians must carefully evaluate individual patient risk factors, disease severity, and the pharmacokinetics of available therapies when weighing the risks and benefits of discontinuing therapy in the perioperative setting.
Similar articles
-
Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?Semin Arthritis Rheum. 2007 Apr;36(5):278-86. doi: 10.1016/j.semarthrit.2006.10.003. Epub 2007 Jan 3. Semin Arthritis Rheum. 2007. PMID: 17204310 Review.
-
Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):10-4. doi: 10.1111/j.1742-7843.2007.00149.x. Epub 2007 Oct 31. Basic Clin Pharmacol Toxicol. 2008. PMID: 17973900 Review.
-
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford). 2006 Dec;45(12):1558-65. doi: 10.1093/rheumatology/kel149. Epub 2006 May 16. Rheumatology (Oxford). 2006. PMID: 16705046
-
Perioperative management of biologic agents used in treatment of rheumatoid arthritis.Am J Ther. 2011 Sep;18(5):426-34. doi: 10.1097/MJT.0b013e3181cb4042. Am J Ther. 2011. PMID: 20216205 Review.
-
Effect of blockade of tumor necrosis factor-alpha with etanercept on surgical wound healing in SWISS-OF1 mice.J Rheumatol. 2009 Oct;36(10):2144-8. doi: 10.3899/jrheum.081285. Epub 2009 Sep 1. J Rheumatol. 2009. PMID: 19723900
Cited by
-
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.World J Gastroenterol. 2012 Jan 21;18(3):197-204. doi: 10.3748/wjg.v18.i3.197. World J Gastroenterol. 2012. PMID: 22294822 Free PMC article. Review.
-
The salvage of knee-exposed prosthesis using neurofasciocutaneous sural flap.Musculoskelet Surg. 2010 May;94(1):33-40. doi: 10.1007/s12306-010-0063-x. Epub 2010 Mar 5. Musculoskelet Surg. 2010. PMID: 20204562
-
IκB kinase β regulates epithelium migration during corneal wound healing.PLoS One. 2011 Jan 17;6(1):e16132. doi: 10.1371/journal.pone.0016132. PLoS One. 2011. PMID: 21264230 Free PMC article.
-
Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.Dig Dis Sci. 2011 Dec;56(12):3610-5. doi: 10.1007/s10620-011-1785-9. Epub 2011 Jun 17. Dig Dis Sci. 2011. PMID: 21681507 Clinical Trial.
-
Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.Rheumatol Int. 2012 Jan;32(1):5-13. doi: 10.1007/s00296-011-2040-6. Epub 2011 Jul 29. Rheumatol Int. 2012. PMID: 21800113
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials